Article
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.
Molecular cancer therapeutics - 1 Oct 2010
Okamoto Wataru, Okamoto Isamu, Tanaka Kaoru, Hatashita Erina, Yamada Yuki, Kuwata Kiyoko, Yamaguchi Haruka, Arao Tokuzo, Nishio Kazuto, Fukuoka Masahiro, Jänne Pasi A, Nakagawa Kazuhiko
Abstract excerpt
Most non-small cell lung cancer (NSCLC) tumors with an activating mutation of the epidermal growth factor receptor (EGFR) are initially responsive to EGFR tyrosine kinase inhibitors (TKI) such as gefitinib but ultimately develop resistance to these drugs. Hepatocyte growth factor (HGF) induces EG...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.